Oncology

Betazymes is directing its innovative enzyme engineering capabilities towards the critical field of oncology, exploring novel enzymatic approaches for cancer diagnostics and therapeutics. Our research focuses on developing highly specific enzymes that can selectively target tumor microenvironments or cancer-specific biomarkers, offering the potential for more precise and less toxic cancer treatments. By leveraging the catalytic power and exquisite selectivity of enzymes, we aim to create innovative tools for early cancer detection, targeted drug delivery, and the development of novel therapeutic strategies that minimize damage to healthy tissues.

In the realm of diagnostics, Betazymes is investigating enzymes that can specifically recognize and interact with cancer-associated antigens or unique metabolic signatures present in tumor cells or bodily fluids. These enzymes can be incorporated into highly sensitive diagnostic assays for early cancer detection and monitoring of treatment response. Our focus is on developing robust and reliable enzymatic diagnostic tools that offer improved accuracy and accessibility compared to traditional methods, ultimately leading to earlier intervention and better patient outcomes.

Harnessing Enzyme Specificity for Targeted Cancer Therapies

For therapeutic applications, our research is centered on engineering enzymes that can directly target and disrupt tumor growth or enhance the efficacy of existing cancer therapies. This includes exploring enzyme-activated prodrug strategies, where a systemically administered inactive drug is converted into its active form specifically within the tumor microenvironment by an engineered enzyme. This targeted activation can significantly reduce systemic toxicity and increase the concentration of the therapeutic agent at the tumor site. We are also investigating enzymes with intrinsic anti-tumor activity, such as those that can selectively degrade components of the tumor microenvironment essential for cancer cell survival and proliferation.

Furthermore, Betazymes is exploring the potential of enzymes in immunotherapy, aiming to develop novel approaches that harness the body's own immune system to fight cancer. This includes investigating enzymes that can modulate the immune response within the tumor microenvironment, making it more conducive to anti-tumor immunity. Our multidisciplinary approach combines expertise in enzymology, molecular biology, and cancer biology to develop innovative enzymatic strategies that hold promise for revolutionizing cancer treatment and improving the lives of patients.

Our commitment to oncology research is driven by the urgent need for more effective and less harmful cancer therapies. By applying our core strengths in enzyme engineering and our passion for scientific innovation, Betazymes is dedicated to making meaningful contributions to the fight against cancer, striving to develop novel enzymatic tools that can improve diagnostics, enhance treatment efficacy, and ultimately lead to better outcomes for cancer patients worldwide.